Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3163-3169

  Rudin, Charles M ^a   Hann, Christine L ^a   Garon, Edward B ^c   Ribeiro De Oliveira, Moacyr ^d   Bonomi, Philip D ^e   Camidge, D Ross ^g   Chu, Quincy ^h   Giaccone, Giuseppe ^b   Khaira, Divis ⁱ   Ramalingam, Suresh S ^j   Ranson, Malcolm R ^k   Dive, Caroline ^l   McKeegan, Evelyn M ^f   Chyla, Brenda J ^f   Dowell, Barry L ^f   Chakravartty, Arunava ^f   Nolan, Cathy E ^f   Rudersdorf, Niki ^f   Busman, Todd A ^f   Mabry, Mack H ^f   Krivoshik, Andrew P ^f   Humerickhouse, Rod A ^f   Shapiro, Geoffrey I ^m   Gandhi, Leena ^m   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PLLC   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f ABBOTT LABORATORIES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ Sunterra Oncology Associates   (United States)

^j EMORY UNIVERSITY   (United States)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

^m DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 19 FRAGMENT ANTIGEN 21 1; NAVITOCLAX; NEURON SPECIFIC ENOLASE; PROGASTRIN RELEASING PEPTIDE; PROTEIN BCL 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECURRENCE; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; THROMBOCYTOPENIA;

EID: 84861482216     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3090     Document Type: Article

References (43)

1. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008;22:1486-92.
2. vonPawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-67. (Pubitemid 29075255)
3. Schiller JH, Adak S, Cella D, DeVore RF III, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive- stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19: 2114-22. (Pubitemid 32366966)
4. D'Angelo SP, Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther 2010;10:1-10.
5. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-37. (Pubitemid 46328466)
6. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54: 6-8. (Pubitemid 24042076)
7. Ikegaki N, Katsumata M, Tsujimoto Y, Nakagawara A, Brodeur GM. Relationship between bcl-2 and myc gene expression in human neuroblastoma. Cancer Lett 1995;91:161-8.
8. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995;177:135-8.
9. Stefanaki K, Rontogiannis D, Vamvouka C, Bolioti S, Chaniotis V, Sotsiou F, et al. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res 1998;18:1167-73. (Pubitemid 28239658)
10. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008;51:6902-15.
11. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
12. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008;14: 3268-77.
13. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81. (Pubitemid 40825512)
14. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67: 1176-83.
15. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, et al. Bcl- 2 family proteins are essential for platelet survival. Cell Death Differ 2007;14:943-51. (Pubitemid 46655455)
16. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007;128:1173-86. (Pubitemid 46427871)
17. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011;29:909-16.
18. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008;14:7813-21.
19. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003;24:209-18. (Pubitemid 37500571)
20. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol 2009;30:121-9.
21. Rudin CM, Mauer A, Smakal M, Juergens R, Spelda S, Wertheim M, et al. Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2011;29:1075-82.
22. Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 2004;24:1941-6. (Pubitemid 38954614)
23. Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003;39:303-13. (Pubitemid 36279450)
24. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 2009;175:808-16.
25. Hou J-M, Krebs MG, Lancashire L, Sloane R, Swain R, Backen A, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small cell lung cancer. J Clin Oncol 2012;30:525-32.
26. Common Terminology Criteria for Adverse Events. Version 3.0. Bethesda, MD: NCI [cited 2012 Apr 25]. Available from: http://ctep.cancer.gov.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
28. Benson AB, Kindler HL, Jodrell D, Hagey A, Coates AI, Meek KA, et al. Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). J Clin Oncol 23:255s, 2005 (suppl; abstr 3537).
29. Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G, et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007;5:331-9. (Pubitemid 46706995)
30. Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, et al. Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2005;92:532-8. (Pubitemid 40395534)
31. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, et al. Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 2006;95:42-8. (Pubitemid 43980552)
32. Breiman L. Bagging predictors. Machine Learning 1996;26:123-40. (Pubitemid 126724382)
33. Devanarayan V, Cummins DJ, Tanzer LR, et al. Application of GAM-and tree models for assessing the role of drug resistance proteins in leukemia chemotherapy. In: Proceedings of the American Statistical Association Joint Statistical Meetings; 1999 Aug 10; Baltimore, MD.
34. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008;68:2321-8. (Pubitemid 351521806)
35. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009;69:3364-73.
36. Shoemaker AR, Oleksijew A, Bauch J, Belli BA, Borre T, Bruncko M, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006;66:8731-9. (Pubitemid 44449190)
37. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol 2009;75:1231-9.
38. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B. Combined Bcl-2/ mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res 2009;15:6096-105.
39. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010;52:1310-21.
40. Jain HV, Meyer-Hermann M. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Res 2011;71:705-15.
41. Zall H, Weber A, Besch R, Zantl N, Hacker G. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer 2010;9:164.
42. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, et al. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 2011;17:1394-404.
43. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2010;2:351-65.